Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Jun 21

PMID 34150655

Citations 8

Authors

Salvatore Crisafulli

Lucrezia Bertino

Andrea Fontana

Fabrizio Calapai

Ylenia Ingrasciotta

Massimiliano Berretta

Gianluca Trifiro

Claudio Guarneri

Affiliations

Soon will be listed here.

Abstract

Cancer is one of the several comorbidities that have been linked with chronic cutaneous inflammatory diseases namely psoriasis/psoriatic arthritis and hidradenitis suppurativa. Although the chronic inflammatory state, typical of the diseases, may induce pro-tumorigenic effects, the debate whether or not the drugs currently used in clinical practice do in facts increase a patient's risk of malignancy remains largely unsolved. The therapeutic armamentarium has been greatly enhanced at least in the last two decades with the advent of biologics, a heterogeneous group of laboratory-engineered agents with more in the pipeline, and other targeted small molecules. Among the organ systems, skin results as one of the most commonly affected, non-melanoma skin cancers being the main drug-induced manifestations as side effect in course of these treatments. The objective of the study is to systematically review the cutaneous malignancy risk of the newer therapies through an overview of meta-analyses and observational studies on the topic.

Citing Articles

A propensity scored case-control analysis of malignant skin cancers and chronic inflammatory disorders.

Kooner A, Sekhon R, Anthony M Arch Dermatol Res. 2025; 317(1):372.

PMID: 39921743 DOI: 10.1007/s00403-025-03877-w.

A state-of-the-art systematic review of cancer in hidradenitis suppurativa.

Abu Rached N, Ruth J, Gambichler T, Ocker L, Bechara F Ann Med. 2024; 56(1):2382372.

PMID: 39046819 PMC: 11271124. DOI: 10.1080/07853890.2024.2382372.

Risk of Skin Cancer in Patients with Psoriasis: Single-Center Retrospective Study Comparing Anti-TNFα and Phototherapy.

Trovato E, Dragotto M, Capalbo E, Cartocci A, Rubegni P, Calabrese L J Clin Med. 2024; 13(9).

PMID: 38730981 PMC: 11084754. DOI: 10.3390/jcm13092452.

Risk of Melanoma and Non-Melanoma Skin Cancer in Patients with Psoriasis and Psoriatic Arthritis Treated with Targeted Therapies: A Systematic Review and Meta-Analysis.

Krzysztofik M, Brzewski P, Cuber P, Kacprzyk A, Kulbat A, Richter K Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38276003 PMC: 10820691. DOI: 10.3390/ph17010014.

Suspected oncologic adverse reactions associated with interleukin-23 inhibitors in EudraVigilance: Comparative study and gender distribution.

Calapai F, Mannucci C, Cardia L, Curro M, Calapai G, Esposito E Pharmacol Res Perspect. 2023; 11(5):e01130.

PMID: 37615258 PMC: 10448453. DOI: 10.1002/prp2.1130.

References

Guarneri C, Bevelacqua V, Polesel J, Falzone L, Cannavo P, Spandidos D . NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma. Oncol Rep. 2017; 37(2):737-746. PMC: 5355753. DOI: 10.3892/or.2017.5362. View

Vaengebjerg S, Skov L, Egeberg A, Loft N . Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2020; 156(4):421-429. PMC: 7042857. DOI: 10.1001/jamadermatol.2020.0024. View

Menter A, Thaci D, Wu J, Abramovits W, Kerdel F, Arikan D . Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. Dermatol Ther (Heidelb). 2017; 7(3):365-381. PMC: 5574748. DOI: 10.1007/s13555-017-0198-x. View

Malaponte G, Signorelli S, Bevelacqua V, Polesel J, Taborelli M, Guarneri C . Increased Levels of NF-kB-Dependent Markers in Cancer-Associated Deep Venous Thrombosis. PLoS One. 2015; 10(7):e0132496. PMC: 4507873. DOI: 10.1371/journal.pone.0132496. View

Moran G, Lim A, Bailey J, Dubeau M, Leung Y, Devlin S . Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013; 38(9):1002-24. DOI: 10.1111/apt.12491. View

Kamata M, Tada Y . Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int J Mol Sci. 2020; 21(5). PMC: 7084606. DOI: 10.3390/ijms21051690. View

Fagerli K, Kearsley-Fleet L, Mercer L, Watson K, Packham J, Symmons D . Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2018; 58(1):80-85. PMC: 6293477. DOI: 10.1093/rheumatology/key241. View

Kelly G, Hughes R, McGarry T, van den Born M, Adamzik K, FitzGerald R . Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol. 2015; 173(6):1431-9. DOI: 10.1111/bjd.14075. View

Di Lernia V, Neri I, Pinton P, Di Nuzzo S, Stingeni L, Guarneri C . Treatment patterns with systemic antipsoriatic agents in childhood psoriasis: an Italian database analysis. G Ital Dermatol Venereol. 2016; 152(4):327-332. DOI: 10.23736/S0392-0488.16.05287-X. View

10.

Polachek A, Muntyanu A, Lee K, Ye J, Chandran V, Cook R . Malignancy in psoriatic disease: Results from prospective longitudinal cohorts. Semin Arthritis Rheum. 2020; 51(1):144-149. DOI: 10.1016/j.semarthrit.2020.12.008. View

11.

Collins L, Asfour L, Stephany M, Lear J, Stasko T . Management of Non-melanoma Skin Cancer in Transplant Recipients. Clin Oncol (R Coll Radiol). 2019; 31(11):779-788. DOI: 10.1016/j.clon.2019.08.005. View

12.

Di Lernia V, Stingeni L, Boccaletti V, Calzavara Pinton P, Guarneri C, Belloni Fortina A . Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis. J Dermatolog Treat. 2015; 27(5):395-8. DOI: 10.3109/09546634.2015.1120852. View

13.

Stern R, Laird N . The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer. 1994; 73(11):2759-64. DOI: 10.1002/1097-0142(19940601)73:11<2759::aid-cncr2820731118>3.0.co;2-c. View

14.

Papp K, Bourcier M, Poulin Y, Lynde C, Gilbert M, Poulin-Costello M . OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States. J Cutan Med Surg. 2018; 22(3):297-303. DOI: 10.1177/1203475418755998. View

15.

DAniello C, Perri F, Della Vittoria Scarpati G, Della Pepa C, Pisconti S, Montesarchio V . Melanoma Adjuvant Treatment: Current Insight and Clinical Features. Curr Cancer Drug Targets. 2017; 18(5):442-456. DOI: 10.2174/1568009617666170208163714. View

16.

Reddy S, Martires K, Wu J . The risk of melanoma and hematologic cancers in patients with psoriasis. J Am Acad Dermatol. 2016; 76(4):639-647.e2. DOI: 10.1016/j.jaad.2016.09.047. View

17.

Lee J, Kim H, Han K, Kim H, Park Y, Lee J . Cancer risk in 892 089 patients with psoriasis in Korea: A nationwide population-based cohort study. J Dermatol. 2018; 46(2):95-102. DOI: 10.1111/1346-8138.14698. View

18.

Facciola A, Venanzi Rullo E, Ceccarelli M, DAndrea F, Coco M, Micali C . Malignant melanoma in HIV: Epidemiology, pathogenesis, and management. Dermatol Ther. 2019; 33(1):e13180. DOI: 10.1111/dth.13180. View

19.

Burmester G, Curtis J, Yun H, FitzGerald O, Winthrop K, Azevedo V . An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. Drug Saf. 2020; 43(4):379-392. PMC: 7105422. DOI: 10.1007/s40264-020-00904-9. View

20.

Stern R, Nichols K, Vakeva L . Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med. 1997; 336(15):1041-5. DOI: 10.1056/NEJM199704103361501. View